Z6×ðÁú

Shenzhen, China. July 7, 2023. Techdow Pharma Italy, a wholly-owned subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or ¡°Hepalink¡±), was recently named a winner of the prestigious annual Le Fonti Award for Excellence in Innovation and Leadership. Mr. Giorgio Foresti, General Manager of Techdow Pharma Italy, and his team received the award at a ceremony attended by prominent business leaders from around the world on June 29, local time, in Milan, Italy.

The renowned Le Fonti Awards are organized by the study center and scientific committee of Le Fonti in Italy and the independent global publisher Le Fonti which was ranked by the Financial Times as the seventh largest media in Europe. Having been established for over a decade with a selection committee of dedicated legal, economic and financial journalists based in over 120 countries worldwide, the Le Fonti Awards are designed to celebrate organizations that demonstrate corporate excellence in the fields of business innovation, leadership, technological achievements and employee engagement, and are recognized as one of the world's leading ceremonies of business awards and personal honors.

Granting Techdow the award for the first time underscores the award committee¡¯s broad recognition of Techdow Pharma Italy¡¯s commitment to providing high quality medicine to patients, as well as the cutting-edge innovation and impressive industrialization capabilities of the Hepalink Group. To date, Techdow Pharmaceutical, the only holding company of Techdow Pharma Italy, has supplied more than 450 million vials of heparin sodium injections to the European market and effectively served countless patients and their families¹.

Mr. Giorgio Foresti, General Manager of Techdow Pharma Italy, said, ¡°We are thrilled and deeply honored to receive such an award with global prestige, as it is a strong recognition of the robust business growth and organizational excellence of Techdow Pharma Italy.¡±

1. Based on 2017- 2023 Q1 statistics from IQVIA database